Orchestra BioMed reports BACKBEAT trial fully enrolled with 349 patients
OBIO•
OBIO•Orchestra BioMed said the BACKBEAT trial has completed enrollment, with 349 patients randomized and primary endpoint data expected in the second quarter of 2027. The company outlined $80.5 million in net public offering proceeds and potential AVIM Therapy approval and US launch in the first half of 2028.
The BACKBEAT trial completed enrollment with 349 patients randomized, and primary endpoint data are due in the second quarter of 2027. The FDA confirmed a PMA supplement pathway for AVIM Therapy; Medtronic will submit following the primary data presentation. Potential FDA approval and a US commercial launch are targeted for the first half of 2028. Orchestra BioMed outlined funding through 2028, including $80.5 million in net public offering proceeds. Enrollment in the Virtue trial is accelerating, with completion targeted by year-end 2027 and 12-month primary endpoint follow-up potentially concluding in the second half of 2028.